Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects This analysis of 2 cohort studies and a mouse model examined the association of clonal hematopoiesis of indeterminate potential with cardiotoxic effects in patients with breast cancer receiving trastu...

Presencia de la hematopoyesis clonal de potencial indeterminado se asocia con una mayor susceptibilidad a los efectos cardiotóxicos relacionados con trastuzumab en pacientes con cáncer de mama #CHIP #cardiotoxic #trastuzumab jamanetwork.com/journals/jam...

DualityBio's HER2-Positive Breast Cancer Therapy Approved for Review in China DualityBio announces their drug Trastuzumab Pamirtecan is approved for review by China's NMPA for treating advanced HER2-positive breast cancer in adults.

DualityBio's HER2-Positive Breast Cancer Therapy Approved for Review in China #China #Shanghai #HER2-positive #DualityBio #Trastuzumab

Long-read #transcriptomics of #GallbladderCancer uncovered ERBB2 i14e, a splice isoform linked to poor prognosis and #trastuzumab resistance; #antisense targeting restored sensitivity, revealing a potential #biomarker and therapeutic strategy.

#STTT: doi.org/10.1038/s413...

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study Triple HER2 blockade with trastuzumab, pertuzumab, and pyrotinib (TPPy) did not improve total pathological complete response (tpCR) rates or breast pathological complete response (bpCR) rates compare....

#Article in @MedComm_MC
Triple #HER2 Blockade With #Trastuzumab, #Pertuzumab, and #Pyrotinib Versus Dual HER2 Blockade in the #Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study doi.org/10.1002/mco2...

#ClinicalTrial

This study uses long-read #transcriptomics in #GallbladderCancer to reveal ERBB2 i14e, a splice variant that boosts ERBB3–AKT signaling, predicts poor prognosis, and drives #Trastuzumab resistance.

#CoverPage in #STTT: doi.org/10.1038/s413...

HER2DX Assay Could Guide Chemotherapy Use in Older Patients with HER2+ Early Breast Cancer The findings suggest that the HER2DX assay could help clinicians decide on the appropriate use of chemotherapy in older patients, study researchers wrote.

The HER2DX Genomic Assay produced long-term prognostic information for older patients with early-stage HER2-positive #breastcancer treated with #trastuzumab, with or without chemotherapy. Published in @natcomms.nature.com.

https://bit.ly/49mKGbb

#bcsm

GeparPiPPa Phase II trial comparing neoadjuvant endocrine therapy in combination with the PI3K-Inhibitor Inavolisib

#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer.
Learn more about the study www.gbg.de/en/trials/ge...

QT Interval and Hormone Receptors Predict Trastuzumab Cardiotoxicity

In 140 HER2‑positive breast cancer patients, 21.4% had LVEF decline; baseline QTc > 450 ms and low estrogen or progesterone receptors predicted cardiotoxicity risk. Read more: getnews.me/qt-interval-and-hormone-... #trastuzumab #cardiotoxicity

Phase III trial on ARX788 versus #lapatinib + #capecitabine (LC) on HER2-positive advanced #BreastCancer patients pretreated with #trastuzumab & taxane showed that ARX788 improves progression free survival compared with LC. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Full-length #Transcriptome revealed a new isoform, ERBB2-i14e, associated with #GallbladderCancer (GBC) progression, worse #prognosis, & #Trastuzumab resistance, highlighting it as a #Biomarker & #TherapeuticTarget for GBC. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Evaluation of the efficacy & safety of adding #Pyrotinib to a #neoadjuvant regimen of #Trastuzumab & #chemotherapy in HER2-positive #BreastCancer patients showed that pyrotinib elicits a beneficial response. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Tumori al seno, anticorpo coniugato in prima linea rallenta la malattia (Adnkronos) - Cala del 44% il rischio che il tumore del seno metastatico Her2 positivo progredisca grazie all’anticorpo farmaco-coniugato in prima linea trastuzumab deruxtecan in associazione a pertuzumab. E’ quanto emerge da uno de...

Tumori al seno, anticorpo coniugato in prima linea rallenta la malattia ... LEGGI TUTTO #Tumori #CancroAlSeno #Her2Positivo #Trastuzumab #Pertuzumab

China's Trastuzumab Rezetecan: A Breakthrough in Treating HER2-Mutant Lung Cancer Trastuzumab rezetecan secures NMPA approval as China's first domestically developed ADC, offering new hope for HER2-mutant non-small cell lung cancer patients.

China's Trastuzumab Rezetecan: A Breakthrough in Treating HER2-Mutant Lung Cancer #China #Shanghai #Hengrui_Pharma #Trastuzumab #HER2_Mutant

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment - OncoDaily FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment / Aditya Bardia, Breast Cancer, cancer, Carlos H. Barrios, FDA, Gargi Patel, Giuseppe

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment
@fda.gov

oncodaily.com/insight/234405

#BreastCancer #Cancer #FDA #OncoDaily #Oncology #Medicine #DESTINY-Breast04Trial #Trastuzumab #Deruxtecan #Health

#Oncotarget reported (Han 2015) breast tumors were reduced by #trastuzumab when combined w/ DPAGT1 inhibitors, even in #Her2 negative cancers. @anviron.bsky.social confirmed this paradox, DPAGT1 inhibitor, ANV221, upregulated Her2 in #TNBC, opening door to potent, targeted TNBC therapeutics.

MedSky🧪#Drugsdiscovery #Cancertherapy The story of #trastuzumab begins with Axel Ullrich’s dedication to the concept that receptor #tyrosinekinases must be the key to many human diseases. It continued with H. Michael Shepard’s dedication to making a #cancertherapy

Happy to have contributed a small part to this study. "Ultrahigh" #HER2 copy number by #dPCR or #RNAseq signals poor response to adjuvant #trastuzumab in breast cancer.

Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab - npj Breast Cancer npj Breast Cancer - Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab

Our new publication online today on dPCR quantification of “#ultrahigh” #HER2 #ERBB2 copy number in early #breastcancer and association to poor response to #trastuzumab. Nice work by #pei_meng #heena_dilal @brueffer.io #sergii_gladchuk #anna_ehinger et al www.nature.com/articles/s41...

Concurrent trastuzumab deruxtecan-induced interstitial lung disease and COVID-19 in the treatment of... Abstract. Patients with cancer are at an increased risk of developing coronavirus disease 2019 (COVID-19) infection. Trastuzumab deruxtecan (T-DXd) is an antibo

MedSky🧪#IDSky #immunoSky #casereport Concurrent #trastuzumab deruxtecan-induced interstitial lung disease & #COVID19 in the treatment of advanced #breastcancer @OxfordMedicalCR

academic.oup.com/omcr/article...